FDA Approval Alert: The Need-to-Know | Trastuzumab Deruxtecan for HER2-Positive Breast Cancer

In May 2022, the FDA approved the use of fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2 treatment in the metastatic, neoadjuvant, or adjuvant setting followed by disease recurrence during treatment or within 6 months of completing therapy.

Sara Hurvitz, MD, Spoke on Efficacy of T-DXd in HER2+ Breast Cancer With Brain Metastases
Sara Hurvitz, MD, Spoke on Efficacy of T-DXd in HER2+ Breast Cancer With Brain Metastases
Video
Jun 1, 2022 12:00 PM
Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.
Sara Hurvitz, MD, on the Benefit of Second-Line T-DXd in Subgroups of HER2+ Breast Cancer
Sara Hurvitz, MD, on the Benefit of Second-Line T-DXd in Subgroups of HER2+ Breast Cancer
Video
May 30, 2022 12:00 PM
Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.
Sara Hurvitz, MD, Speaks to Improvements in Treatment for HER2+ Breast Cancer
Sara Hurvitz, MD, Speaks to Improvements in Treatment for HER2+ Breast Cancer
Video
May 29, 2022 2:00 PM
Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.
Sara Hurvitz, MD, Discusses the Full Approval of Second-Line T-DXd in HER2+ Breast Cancer
Sara Hurvitz, MD, Discusses the Full Approval of Second-Line T-DXd in HER2+ Breast Cancer
Video
May 26, 2022 12:00 PM
Sara Hurvitz, MD, spoke about to recent approval of fam-trastuzumab deruxtecan-nxki in the second-line setting for patients with HER2-positive breast cancer.
Findings from the phase 3 DESTINY-Breast03 trial have led to the FDA approval of fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.
Trastuzumab Deruxtecan Receives FDA Approval for Metastatic HER2+ Breast Cancer
Article
May 5, 2022 1:25 PM
Findings from the phase 3 DESTINY-Breast03 trial have led to the FDA approval of fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.